ISSN 1866-8836
Клеточная терапия и трансплантация

Clinical efficiency and safety of tramadol and low-dose morphine to manage pain syndromes in children following chemotherapy and hematopoietic stem cell transplantation

Ekaterina V. Goncharova1,2, Inga E. Zavodova1, Nikita P. Volkov1, Olga A. Ivanova1, Maxim A. Kucher1, Alexey Y. Sokolov2,3, Maxim P. Bogomolny1, Gleb E. Ulrikh4, Ludmila S. Zubarovskaya1, Boris V. Afanasyev1

1 RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, St. Petersburg, Russia
2 Department of Neuropharmacology, Valdman Institute of Pharmacology, Pavlov University, St. Petersburg, Russia
3 Pavlov Institute of Physiology of the Russian Academy of Sciences, St. Petersburg, Russia
4 Department of Anesthesiology and Pediatric Intensive Care, Saint Petersburg State Pediatric Medical University, St. Petersburg, Russia

Dr. Ekaterina V. Goncharova, RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University, L.Tolstoy St. 6-8, 197022, St. Petersburg, Russia
Phone: +7 (911) 087 8976

doi 10.18620/ctt-1866-8836-2020-9-2-20-27
Submitted 07 May 2020
Accepted 05 June 2020


A sufficient subgroup of patients encounters pain syndrome in the course of cytostatic chemotherapy (ChT), either with or without hematopoietic stem cell transplantation (HSCT). Over this time period, severe thrombocytopenia and leucopenia may develop, thus limiting the opportunities for non-steroidal anti-inflammatory drugs (NSAID). As recommended by WHO, administration of strong opioids to children is possible in moderate pain and inefficiency of NSAIDs. In this case, second step of the pain relief ladder is absent, i.e., codeine application. However, the recommendations do not exclude usage of tramadol, which is widely applied in pediatrics. Our aim was to evaluate relative safety and efficiency of tramadol and morphine in managment of moderate pain in children after HSCT and ChT.

Patients and methods

The study included analysis of 159 children admitted to the ICU pain management team with complaints for weak or moderate pain (form 3 to 6 points on an age-matched scale). The age of patients was from 1 to 17 years, with a median of 8 years old. All the patients did not receive opioids (were opioid naïve) within 30 days before inclusion to the study. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1st-line therapy (0.2 to 0.3 mg/kg/h). The patients form 2nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). Treatment efficiency was assessed by FLACC verbal scores, Wong-Baker Faces Pain Rating Scale, or visual analogue scale and quality of life. Statistical evaluation was performed by means of SPSS software, using a nonparametric Chi-square criterion.


When administered tramadol as a first-line therapy, it was efficient in ca. 40.7% of cases (n=48). With low-dose morphine, the response rate proved to be 58.5% (n=24). One patient (0.8%) received tramadol when transferred to other institution. The second-line therapy (strong opioids) was administered due to lack of efficiency, or poor drug acceptability during the first-line treatment. It was observed in 53.4% of group 1 (n=63), and in 39% (n=16) of morphine-treated patients (group 2). Side effects due to tramadol administration were observed in 5.1% of cases (n=6). When administered low-dose morphine, only 1 female patient (2.4%) developed intestinal paresis which resolved after the therapy cancellation. Upon statistical evaluation, no significant differences were revealed between the groups.


Both medical drugs have shown similar efficiency and safety when applied for jugulating weak or moderate nociceptive pain after cytostatic chemotherapy and HSCT in pediatric patients.


Chemotherapy, anticancer, pain syndrome, mucositis, tramadol, morphine, efficiency, safety.


Survival rates of children and adolescents with oncological diseases significantly improved due to development of novel chemotherapy (ChT) protocols. In large part, this could be explained by more aggressive treatment, thus requiring a more careful selection of supportive and symptomatic therapy. Pain is among the most common symptoms which trouble both sick children themselves, and their parents [1].

Hematopoietic stem cell transplantation (HSCT) is a high-risk treatment aimed for therapy of both oncological, non-malignant hematological and some orphan diseases. Early post-transplant period is accompanied by such common conditions, e.g., weakness, pains and insomnia. These complaints are presented in 8 to 55% of autologous HSCTs [2], and 60 до 80% of allogeneic HSCT recipients [3]. Oral and gastrointestinal mucositis is among common painful complications occurring in 20 to 40% of chemotherapy (ChT) courses, and in up to 80% cases of conditioning treatment preceding HSCT, dependent on the drug combination applied [4].

Cytotoxic drugs used for conditioning therapy before allo-HSCT could damage endothelium of liver with subsequent development of veno-occlusive disease which could manifest with hepatomegaly accompanied by right upper quadrant pain due to extensive distension of Glisson capsule. This complication may encounter in 13.7% cases of HCST, as well as after ChT course [5]. In our experience, pain syndromes may be also connected with development of acute hemorrhagic cystitis, infections, fast engraftment, bone marrow necrosis, bone pain associated with corticosteroid withdrawal etc.

Thrombocytopenia, agranulocytosis, and, sometimes, renal dysfunction comprise special features in the patients after HSCT and some ChT regimens, thus limiting the opportunities for usage of nonsteroid anti-inflammatory drugs (NSAID), as first step of WHO analgetic ladder. Administration of these medicines as analgetics, could also hide fever of infectious origin. One should also note limited routes for administration of painkillers, i.e., per oral uptake could be difficult due to evolving mucositis. Rectal administration is not recommended, because of high-risk translocation of gut microflora in neutropenic conditions, whereas intramuscular injections are contraindicated, due to thrombocytopenia and painful manipulation [6, 7]. In this view, management of weak and moderate pain with NSAID may be difficult, and one should change the therapy for second-line treatment at early stages. Previously, WHO has excluded the second stage of pain relief ladder using weak opioids, e.g., codeine [7]. From 2009 to 2012, several cases of breath depression were registered in children under 5 years old after codeine postoperative analgesia after tonsillectomy. Most likely, this side effect was associated with individual genetic feature of cytochrome enzymes e.g., ultra-fast codeine activation by CYP2D6 with excessive production of morphine which, under normal excretion rates, could be accumulated at toxic concentrations.

In particular, tramadol is mostly inactivated by two enzymes, CYP2D6 and CYP3A4, whereas unchanged М1 metabolite, is, in turn, is excreted with urine. The analgetic effects of the drug are explained by, at least, two mechanisms, i.e., interaction between tramadol/M1 metabolite and μ-opiate receptors (OPRM1), as well as inhibition of serotonin and norepinephrine reuptake by tramadol, thus suppressing pain impulse transmission at the level of spinal cord [8, 9]. Undoubtedly, the patients with ultra-fast tramadol metabolism are in high-risk group, especially, in cases of high-dose treatment and appropriate comorbidities of respiratory system, sleep apnea in tonsillar hyperplasia, or obesity conditions [10]. Therefore, some authors recommend to admit the patients to inpatient unit as early as 24 hours before treatment, in cases of acute nociceptive pain in patients administered tramadol and uncertain CYP2D6 activity levels [11]. Concerning the analgetic capacity, tramadol takes an intermediate position between NSAID and potent opioids, but at the same time, some publications report on less common frequency of sedation, respiratory depression, constipation and other side effects typical to strong opioids [12]. At the present time, tramadol is widely used for treatment of nociceptive pain in traumas and after surgical interventions in children [13, 14, 15, 16, 17, 18]. For moderate pain, the WHO analgesia ladder presumes low doses of strong opioids (oxycodone or morphine) to be the main alternative for weak opioids.

High individual variability of efficient dose is a specific feature of morphine administration. This characteristic could be explained by differences in its bioavailability, metabolism and excretion. The main morphine metabolites are as follows: morphine-6-glucuronide, which exhibits higher analgetic ability, but can elicit nausea, vomiting, excessive sedation, as well as morphime-3-glucuronide with probable antianalgetic and neurotoxic effects [19]. Several studies report about efficiency and safety of low-dose-morphine when managing moderate pain, e.g., in pediatric practice [20, 21, 22, 23]. In turn, the adverse effects of morphine derivatives are not shown at the present time (19).

Worth of note, however, both morphine and tramadol, may also display some side effects, including nausea, vomiting, respiratory depression, urinary retention, constipation, skin itching etc., thus causing discomfort to the patient [24, 25]. Therefore, the aim of our study was to evaluate efficiency and safety of tramadol and low-dose morphine in the treatment of moderate pain in children.

Patients and methods


Figure 1. Patients age distribution


Figure 2. Distribution of main causes of pain

The study was conducted in the Anesthesiology Department of R. M. Gorbacheva Memorial Institute for Pediatric Hematology, Oncology and Transplantation. The study included 159 primary admittances of the patients 1 to 17 years old (a median of 8 years) with complaints of moderate pain. Their age distribution is shown in Fig. 1.

The diagnoses were as follows: solid malignancies, 55.4% (n=88); hemoblastoses, 35.2% (n=56); non-malignant hematological disorders, 5% (n=8) and orphan diseases 4.4% (n=7).

Of them, 13.8% (n=22) were subjected to ChT, 68.8% (n=109) underwent allo- or auto-HSCT with myeloablative treatment regimen; 17.6% (n=28) received HSCT with non-myeloablative conditioning. The main reasons for pain syndrome were: mucositis, 85.5% (n=136), bone pain associated with hematopoiesis recovery, 5% (n=8); progression of primary disease, 5% (n=8); intestinal graft-versus-host disease (GvHD) 1.3%, (n=2), mucositis combined with acute cystitis 2.5% (n=4); paraproctitis, 0.7% (n=1), as seen in Fig. 2.

The intensity if pain was evaluated 3 times a day throughout the observation period to age-matched scale adapted to abilities of the patient (FLACC, verbal scale, Wong-Baker Faces Pain Rating Scale, or visual analogue scale). The total time of observation, including, changing lines of analgesic therapy, if necessary, ranged from 1 to 20 days (median 6 days). The response to therapy was assessed integrally by such parameters as: pain intensity (permanent and activity-evoked), quality of night sleep, ability of food and drink intake without an pain related failure, the possibility of non-pharmacological treatment and patient satisfaction. All the patients were classified into 2 groups in a ratio 3:1. The drugs were injected by continuous infusion at the inpatient clinic. In the first group (n=118), standard tramadol doses were administered as the 1st-line therapy (0.2 to 0.3 mg/kg/h). The patients in the 2nd group (n=41) were administered low-dose morphine (0.01 to 0.019 mg/kg/h). The initially prescribed analgetic was the first line of therapy, if there was a change of therapy, then the new analgetic was considered the second line of therapy. Drug infusion was performed permanently, via central venous catheter under hospital conditions. Pain intensity and drug acceptability were evaluated 2-3 times a day. In cases of insufficient analgesia, i.e., non-reduced or enhanced pain, lack of food and fluid intake because of pain etc., the drug was changed, or morphine dosage was increased. The analgetics were also changed in case of bad tolerance of current therapy. The choice of drug was made individually, depending on clinical situation.

Statistical evaluation was performed by means of SPSS software, using Chi-square test. When checking statistical hypotheses, the difference was presumed significant by p<0.05.


The results of our study have revealed that the therapy was effective in 40.7% (n=48) and 58.5% (n=24) for tramadol and low-dose morphine treatment respectively, whereas in 0.8% of the cases, tramadol administration was prolonged to the end of staying in the unit/transfer to hospice, with good therapy acceptability. Enhanced analgetic treatment was required in 53.4% (n=63) for the 1st group versus 39.0% (n=16) for the patients in the 2nd group (Table 1).

Table 1. First line therapy results


Adverse effects in the first (tramadol-treated) group were observed in 5.1% (n=6). In particular, we observed one case of somnolescence with subsequent excitation in a girl of 4 years old; one case of dizziness with tremor in a girl of 11 years old. Two cases of involuntary contractions of striated muscles were detected: a 6 years old girl had twitching of right hand by 2 days after tramadol injections, and a 10 years old boy developed involuntary contractions of mimic muscles after 3 days of treatment, probably, due to serotoninergic effect of the drug. We have also seen one case of vomiting and nausea in the 17 years old female, as well as a case of nausea and anxiety in the 16 years old female. At the next treatment courses, this pain management was based on strong opioids. Their injection was accompanied by similar side effects. However, the mentioned side effects were no health-threatening. Subsequently 6 years old girl required the change of therapy to fentanyl. In other cases after cancellation of tramadol infusion, weak pain persisted, but further analgesia was not necessary. In the second group, only one female patient (2.4% of total) treated with low-dose morphine developed intestinal paralysis that was resolved after the therapy change.

Upon statistical analysis with Chi-square method, no significant differences were found between the tramadol group and low-dose morphine-treated groups in effectiveness and frequency of side effects (p=0.237).

In case of inefficiency of tramadol or low doses of morphine the second line of therapy included morphine in a low dose (after tramadol administration) was used in 29.1% (n=23), morphine in a standard dose (from 0.02 mg/kg/hr) in 17.7% (n=14) or fentanyl at a dose of 0.05 mcg/kg/hr in 53.2% (n=42) (Table 2).

Table 2. Distribution of the 2nd line therapy medicines


We also evaluated the safety of low and standard doses of morphine in the second line of pain management therapy (Table 3). As result, we observed that side effects appeared in two cases: one because of nausea and vomiting and one due to complaints of blurred focus of vision, which was possibly associated with myosis. In group of standard doses of morphine one case of postrenal urinary retention. All three cases required a revision of treatment.

Table 3. Results of second line therapy with morphine in low and standard doses


Upon statistical analysis with Chi-square method, no significant differences were found between the standard and low-dose morphine-treated patients in effectiveness and frequency of side effects (p=0.271).


Currently, some authors state that the respiratory depression is rarely encountered when tramadol dosage is carefully maintained [26, 27]. Frequency of nausea and vomiting are compatible (10-40%) when administering tramadol or opioids [28]. In our experience, a case of intestinal paralysis should be noted in a female patient from 2nd group with mucositis. She had also side effects in the course of immune suppressors (nephro- and neurotoxicity), as well as pancytopenia and hemorrhagic syndrome that could be risk factors of this condition. Concerning adverse effects associated with tramadol prescription, the literature presents only single cases of generalized cramps due to excessive dosage and drug administration to a child under 1 year old [29]. One may also suggest an evolving serotonin syndrome connected to high dosage of serotoninergic drugs (selective serotonin reuptake inhibitors, some monoamine oxidase inhibitors), which includes excitation, ataxia, increased sweating, diarrhea, fever, hyperreflexia, and tremor. In our study, similar symptoms were seen in 4 patients, however, at less significant. This is, probably, connected with non-opioid effects of the drug (inhibition of serotonin and norepinephrin reuptake) [30, 31]. However, one cannot exclude ultra-fast CYP2D6 activity. That is the key aspects influencing tramadol efficiency and, potentially, genetic studies could serve as a predictor of efficacy and safety of the drug. Meanwhile, the CYP2D6 gene polymorphism is quite variable and requires time-consuming molecular genetic studies, thus reducing value of this technique in case of acute pain. One should also understand that the genotype will correspond to phenotype, with regard to variable clearance and body weight [8]. Therefore, we observe the children at the hospital within first 24 hours after starting tramadol infusion. For the patients requiring longer analgesia period, than in our study, tramadol shows lesser potential risk of dependence compared to classical opioids [32]. It’s also important to note that administration of tramadol has a less strict legal regulation [33, 34]. Due to social prejustice, its administration causes lesser anxiety on the part of parents and adolescent patients with respect to adverse effects, ex., addiction. Similarly, in cases with inefficiency of this therapy, the parents take easier administration of strong opioids [35, 36]. In future, tapentadol and local morphine applications could be promising therapeutic options [37]. However, there are only modest data on the studies of these medications in children and adolescents.


Based on the study data, we may suggest that tramadol exerts analgetic effects which are comparable to low-dose morphine. However, administration of these drugs needs dynamic observation of pediatric patients in the hospital at initial steps of therapy, due to some features of individual response and probable side effects. These issues also require further studies in larger groups of patients.

Authors are grateful to Elena V. Verbitskaya, assistant professor of the department of clinical pharmacology and evidence-based medicine, for her help in statistical data processing.

Conflict of interests

The authors declare no conflicts of interest.


  1. Tutelman PR, Chambers CT, Stinson JN, Parker JE, Fernandez CV, Witteman HO, Nathan PC, Barwick M, Campbell F, Jibb LA, Irwin K. Pain in children with cancer: prevalence, characteristics, and parent management. Clin J Pain. 2018 ;34(3):198-206.
  2. Anderson KO, Giralt SA, Mendoza TR, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39(12):759-66.
  3. Bevans MF, Mitchell SA, Marden S. The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer. 2008;16(11):1243-1254.
  4. Bowena JM, Wardill HR. Advances in the understanding and management of mucositis during stem cell transplantation. Curr Opin Support Palliat Care. 2017; 11(4), 341-346.
  5. Richardson PG, Grupp SA, Pagliuca A, Krishnan AJ, Ho VT, Corbacioglu S. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. Int J Hematol Oncol. 2017; 6(3):75-93.
  6. Ma JD, El-Jawahri AR, LeBlanc TW, Roeland EJ. Pain syndromes and management in adult hematopoietic stem cell transplantation. Hematol Oncol Clin North Am. 2018; 32 (3), 551-567.
  7. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: World Health Organization; 2012.
  8. Allegaert K, Holford N, Anderson BJ, Holford S, Stuber F, Rochette A, Trocóniz IF, Beier H, de Hoon JN, Pedersen RS, Stamer U. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. Clin Pharmacokinet. 2015; 54(2):167-178.
  9. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth Analg. 2017;124(1):44-51.
  10. Anderson BJ, Thomas J, Ottaway K, Chalkiadis GA. Tramadol: keep calm and carry on. Pediatr Anesth. 2017;27:785‐788.
  11. Rodieux F, Vutskits L, Posfay-Barbe KM, Habre W, Piguet V, Desmeules JA, Samer CF. When the safe alternative is not that safe: tramadol prescribing in children. Front. Pharmacol. 9:148. DOI: 10.3389/fphar.2018.00148.
  12. Marzuillo P, Calligaris L, Barbi E. Tramadol can selectively manage moderate pain in children following European advice limiting codeine use. Found Acta Pædiat. 2014; 103:1110-1116.
  13. Ali S, Sofi K, Dar AQ. Comparison of intravenous infusion of tramadol alone with combination of tramadol and paracetamol for ostoperative pain after major abdominal surgery in children. Anesth Essays Res. 2017; 11:472–476. DOI: 10.4103/aer.AER_23_17.
  14. Friedrichsdorf SJ, Postier AC, Foster LP, Lander TA, Tibesar RJ, Lu Y, Sidman JD. Tramadol versus codeine/acetaminophen after pediatric tonsillectomy: a prospective, double-blinded, randomized controlled trial. J Opioid Manag. 2015; 11: 283-294. DOI: 10.5055/jom.2015.027.
  15. Liaqat N, Dar SH. Comparison of single-dose nalbuphine versus tramadol for postoperative pain management in children: a randomized, controlled trial. Korean J Anesthesiol. 2017; 70: 184-187. DOI: 10.4097/kjae.2017.70. 2.184.
  16. Schnabel A, Reichl SU, Meyer-Friessem C, Zahn PK, Pogatzki-Zahn E. Tramadol for postoperative pain treatment in children. Cochrane Database Syst Rev. 2015; 3:CD009574. DO: 10.1002/14651858.CD009574.pub2.
  17. Yenigun A, Et T, Aytac S, Olcay B. Comparison of different administration of ketamine and intravenous tramadol hydrochloride for postoperative pain relief and sedation after pediatric tonsillectomy. J Craniofac Surg. 2015; 26: e21-e24. DOI: 10.1097/scs.0000000000001250.
  18. Neri E, Maestro A, Minen F, Montico M, Ronfani L, Zanon D, Favret A, Messi G, Barbi E. Sublingual ketorolac versus sublingual tramadol for moderate to severe posttraumatic bone pain in children: a double-blind, randomised, controlled trial. Arch Dis Child. 2013; 98: 721-724. DOI: 10.1136/archdischild-2012-303527.
  19. Lee YJ, Suh S-Y, Song J, Lee S, Seo A-R, Ahn HY, Lee MA, Kim C-M, Klepstad P. Serum and urine concentrations of morphine and morphine metabolites in patients with advanced cancer receiving continuous intravenous morphine: an observational study. BMC Palliat Care. 2015; 14: 53. DOI:10.1186/s12904-015-0052-9.
  20. Bandieri E, Romero M, Ripamonti C, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2016;34(5):436-442. DOI: 10.1200/JCO.2015.61.0733.
  21. Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G. Use of strong opioids in advanced cancer pain: A randomized trial. J Pain Symptom Managem. 2004; 27:409-416.
  22. Maltoni M, Scarpi E, Modonesi C, Passardi A, Calpona S, Turriziani A, Speranza R, Tassinari D, Magnani P, Saccani D, Montanari L, Roudnas B, Amadori D. A validation study of the WHO analgesic ladder: A two-step vs three-step strategy. Support Care Cancer.2005; 13: 888-894.
  23. Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Ficorella C, Verna L, Tirelli W, Villari P, Arcuri E. Low morphine doses in opioid naive cancer patients with pain. J Pain Symptom Managem. 2006; 31:242-247.
  24. Duedahl TH, Hansen EH. A qualitative systematic review of morphine treatment in children with postoperative pain. Paediatr Anaesth. 2007; 17: 756-774.
  25. Verghese ST, Hannallah RS. Acute pain management in children. J Pain Res. 2010; 3:105-123.
  26. Hannam JA, Anderson BJ, Potts A. Acetaminophen, ibuprofen, and tramadol analgesic interactions after adenotonsillectomy. Pediatr Anesth. 2018; 28(10): 841-851. DOI: 10.1111/pan.13464.
  27. Hassanian-Moghaddam H, Farnaghi F, Rahimi M. Tramadol overdose and apnea in hospitalized children, a review of 20 cases. Res Pharm Sci. 2015; 10(6):544-552.
  28. Allegaert K, Rochette A, Veyckemans F. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Pediatr Anesth. 2011; 21:266-273.
  29. Li X, Zuo Y, Dai Y. Children's seizures caused by continuous intravenous infusion of tramadol analgesia: Two rare case reports. Pediatr Anesth.2012; 22 (3):308-309.
  30. Savage R. Medical assessor serious reactions with tramadol: Seizures and serotonin syndrome. Prescriber Update. 2007; 28(1): 11-13.
  31. Sansone RA, Sansone LA. Tramadol: Seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont). 2009; 6 (4): 17-21.
  32. Kirienko P.A. Usage if tramadol hydrochloride in routine clinical practice (review of literature). Rossiisky Medizinskyi Zhurnal. 2004; 8:512 (In Russian).
  33. Order of the Ministry of Health of Russian Federation of January 14/2019 №4N "On Approving the Procedure for Prescribing Medicines, Forms of Prescription Forms for Medicines Procedure for Formulating the Forms. Recording and Storage", enactment date: 28.05.2020.,0&rnd=0.7542220165183926#0878938710536209 (In Russian).
  34. Appendix No.2 to the Disposal of Russian Government of 12.10.2019 № 2406-r. (In Russian).
  35. Sichetti D, Bandieri E, Romero M, Di Biagio K, Luppi M, Belfiglio M, Tognoni G, Ripamonti CI. ECAD Working Group: Impact of setting of care on pain management in patients with cancer: a multicentre cross-sectional study. Ann Oncol. 2010; 21(10):2088-2093.
  36. Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, Apolone G. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol. 2014; 32(36):4149-4154.
  37. Kolesnikov YA. Prospective usage of a combination of locally injected nonsteroid anti-inflammatory drugs and opioids when treating pains of peripheral genesis. Vestnik Anestesiologii I Reanimatologii. 2019; 16(3):41-47 (In Russian).
Volume 9, number 2

Download PDF version

doi 10.18620/ctt-1866-8836-2020-9-2-20-27
Submitted 07 May 2020
Accepted 05 June 2020

Back to the list